Deutsche Bank AG Grows Holdings in Artivion, Inc. (NYSE:AORT)

Deutsche Bank AG lifted its stake in Artivion, Inc. (NYSE:AORT) by 45.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 36,982 shares of the company’s stock after acquiring an additional 11,501 shares during the quarter. Deutsche Bank AG owned 0.09% of Artivion worth $1,057,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Wasatch Advisors LP raised its position in Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after purchasing an additional 226,160 shares during the period. First Trust Advisors LP acquired a new stake in shares of Artivion in the fourth quarter valued at $4,771,000. Next Century Growth Investors LLC raised its holdings in shares of Artivion by 29.7% in the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock valued at $14,085,000 after buying an additional 112,918 shares during the period. Lord Abbett & CO. LLC lifted its stake in Artivion by 40.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 306,702 shares of the company’s stock worth $8,769,000 after acquiring an additional 88,902 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Artivion by 64.2% during the 4th quarter. JPMorgan Chase & Co. now owns 160,796 shares of the company’s stock worth $4,597,000 after acquiring an additional 62,893 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insider Activity

In other news, insider John E. Davis sold 15,100 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the sale, the insider now owns 208,778 shares in the company, valued at approximately $4,929,248.58. The trade was a 6.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 9,926 shares of the company’s stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $29.00, for a total transaction of $287,854.00. Following the completion of the transaction, the senior vice president now owns 187,258 shares of the company’s stock, valued at approximately $5,430,482. The trade was a 5.03% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,066 shares of company stock worth $1,389,017. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp upgraded shares of Artivion to a “strong-buy” rating in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Price Performance

AORT stock opened at $28.64 on Monday. The business’s 50-day moving average is $25.13 and its two-hundred day moving average is $27.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm has a market capitalization of $1.22 billion, a P/E ratio of -1,432.00 and a beta of 1.54. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $32.33.

Artivion (NYSE:AORT) last released its earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $98.98 million for the quarter, compared to analysts’ expectations of $94.81 million. Analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.